Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Debt to Equity (2020 - 2023)

C4 Therapeutics (CCCC) has 4 years of Debt to Equity data on record, last reported at $0.04 in Q2 2023.

  • For Q2 2023, Debt to Equity rose 37.01% year-over-year to $0.04; the TTM value through Jun 2023 reached $0.04, up 37.01%, while the annual FY2022 figure was $0.04, 43.63% up from the prior year.
  • Debt to Equity reached $0.04 in Q2 2023 per CCCC's latest filing, up from $0.04 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.04 in Q2 2023 and bottomed at -$0.06 in Q3 2020.
  • Average Debt to Equity over 4 years is $0.03, with a median of $0.03 recorded in 2022.
  • The widest YoY moves for Debt to Equity: up 141.91% in 2021, down 22.8% in 2021.
  • A 4-year view of Debt to Equity shows it stood at $0.04 in 2020, then dropped by 22.8% to $0.03 in 2021, then surged by 43.63% to $0.04 in 2022, then increased by 11.4% to $0.04 in 2023.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $0.04 in Q2 2023, $0.04 in Q1 2023, and $0.04 in Q4 2022.